Abstract
Many medical conditions can now be effectively resolved with the use of transplanted cells, tissues or organs. Numerous other conditions are the targets of ongoing preclinical and clinical transplantation research. Despite the remarkable success of transplantation therapies, a number of issues hamper their use in widespread clinical practice (EDGINGTON 1992a,b; KOLLER and PALSSON 1993; LANGER and VACANTI 1993; EMERSON 1996). First, the demand for organs and tissues from suitable donors to be used in allogeneic (non-self) transplantation has far outweighed their availability. Consequently, investigators have increasingly turned to the use of autologous (the patient’s own) cells and tissues, or to the use of xenogeneic (non-human) materials for transplantation therapies. Second, transplantation procedures continue to be cost prohibitive for otherwise medically warranted applications. Third, the procurement of suitable tissues is often prohibitively invasive for the donor, in many cases requiring cadaveric material to be used. As a result, the full potential of transplantation therapies has not yet been realized.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bortin MM, Horowitz MM, Rimm AA (1992) Progress report from the international bone marrow transplant registry. Bone Marrow Transplant 10: 113 – 122
Edgington SM (1992a) New horizons for stem-cell bioreactors. Biotechnology 10: 1099 – 1106
Edgington SM (1992b) 3-D biotech: tissue engineering. Biotechnology 10:855–860
Emerson SG (1996) Ex vivo expansion of hematopoietic precursors, progenitors, and stem cells: The next generation of cellular therapeutics. Blood 87: 3082 – 3088
FDA (1993) Medical devices; current good manufacturing practice (cGMP) regulations; proposed revisions; request for comments; proposed rule. Federal Register 58: 61952 – 61986
Fleischaker RJ Jr, Sinskey AJ (1981) Oxygen demand and supply in cell culture. Eur JAppi Microbiol Biotechnol 12: 193 – 197
Haylock DN, To LB, Dowse TL, Juttner CA, Simmons PJ (1992) Ex vivo expansion and maturation of peripheral blood CD34+ cells into the myeloid lineage. Blood 80: 1405 – 1412
Klingemann H-G, Deal D, Reid D, Eaves CJ (1993) Design and validation of a clinically applicable culture procedure for the generation of interleukin-2 activated natural killer cells in human bone marrow autografts. Exp Hematol 21: 1263 – 1270
Koller MR, Emerson SG, Palsson BØ (1993) Large-scale expansion of human stem and progenitor cells from bone marrow mononuclear cells in continuous perfusion culture. Blood 82: 378 – 384
Koller MR, Palsson MA, Manchel I, Palsson BØ (1995) LTC-IC expansion is dependent on frequent medium exchange combined with stromal and other accessory cell effects. Blood 86: 1784 – 1793
Koller MR, Manchel I, Palsson MA, Mäher RJ, Palsson BØ (1996) Different measures of ex vivo human hematopoietic culture performance are optimized under vastly different conditions. Biotechnol Bioeng 50: 505 – 513
Koller MR, Palsson BØ (1993) Tissue engineering: reconstitution of human hematopoiesis ex vivo. Biotechnol Bioeng 42: 909 – 930
Langer R, Vacanti JP (1993) Tissue engineering. Science 260: 920 – 926
Mulligan RC (1993) The basic science of gene therapy. Science 260: 926 – 932
Naughton BA (1995) The importance of stromal cells. In: Bronzino JD (ed) The biomedical engineering handbook. CRC Press, Boca Raton, pp 1710 – 1727
Palsson BØ, Paek S-H, Schwartz RM, Palsson M, Lee G-M, Silver SM, Emerson SG (1993) Expansion of human bone marrow progenitor cells in a high cell density continuous perfusion system. Biotechnology 11: 368 – 371
Peng C-A, Palsson B– (1996) Determination of specific oxygen uptake rates in human hematopoietic cultures and implications for bioreactor design. Ann Biomed Eng 24:
Schwartz RM, Palsson BØ, Emerson SG (1991) Rapid medium perfusion rate significantly increases the productivity and longevity of human bone marrow cultures. Proc Natl Acad Sci USA 88: 6760 – 6764
Sutherland HJ, Hogge DE, Cook D, Eaves CJ (1993) Alternative mechanisms with and without steel factor support primitive human hematopoiesis. Blood 81: 1465 – 1470
Verfaillie CM (1993) Soluble factor(s) produced by human bone marrow stroma increase cytokine-induced proliferation and maturation of primitive hematopoietic progenitors while preventing their terminal differentiation. Blood 82: 2045 – 2053
Zandstra PW, Eaves CJ, Piret JM (1994) Expansion of hematopoietic progenitor cell populations in stirred suspension bioreactors of normal human bone marrow cells. Biotechnology 12: 909 – 914
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Armstrong, R.D., Koller, M.R., Maluta, J., Ogier, W.C. (1999). Clinical Systems for the Production of Cells and Tissues for Human Therapy. In: Oxender, D.L., Post, L.E. (eds) Novel Therapeutics from Modern Biotechnology. Handbook of Experimental Pharmacology, vol 137. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59990-3_10
Download citation
DOI: https://doi.org/10.1007/978-3-642-59990-3_10
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-65927-3
Online ISBN: 978-3-642-59990-3
eBook Packages: Springer Book Archive